Research Protocol for Assessment of Solitary and Combined effect of Guduchi and Punarnava on Structural and Functional Changes of Ageing in Liver and Kidney in Wistar Rats

Kalpana Tawalare1*, Pradnya Dandekar2, Priti Desai3 and Kiran Tawalare4

1Department of Rachana Sharir, Bhausaheb Mulak Ayurved College and RH, Butibori, Nagpur, India.  
2Department of Kriya Sharir, Mahatma Gandhi Ayurved College, Salod, Datta Meghe Institute of Medical Sciences, Wardha, India.  
3Department of Rachana Sharir, Mahatma Gandhi Ayurved College, Salod, Datta Meghe Institute of Medical Sciences, Wardha, India.  
4Department of Kriya Sharir, Shri Ayurved College, Nagpur, India.

Authors’ contributions:  
This work was carried out in collaboration among all authors. Author KT designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors PDD and PD managed the analyses of the study. Author KT managed the literature searches. All authors read and approved the final manuscript.

Article Information  
DOI: 10.9734/JPRI/2021/v33i30A31630  
Editor(s):  
(1) Dr. Prem K. Ramasamy, Brandeis University, USA.  
Reviewer(s):  
(1) Bandameedi Ramu, Mewar University, India.  
(2) Sobha Rani, Karnataka Veterinary, Animal and Fisheries Sciences University, BIDAR, India.  
(3) K. R. Chandrashekar, Yenepoya (Deemed to be University), India.  
Complete Peer review History: http://www.sdiarticle4.com/review-history/68579

Study Protocol

ABSTRACT

**Background:** The liver and kidney play a central role in metabolic and detoxification processes, which may hamper the functional ability of these organs. Acharya Charaka suggests to use drugs of vayasthapana mahakashaya in different combinations to prevent ageing. *Guduchi* (Tinospora cardifolia) and *punarnava* (Boerhavia diffusa) are two drugs chosen to evaluate the solitary and combined effect on structural and functional changes in liver and kidney of Wistar rat.

*Corresponding author: E-mail: drkalpanatawalare@gmail.com;
INTRODUCTION

The process of aging refers to the decay of an organism’s structure and function, in which molecular and cellular modification can have various effects at the individual level with time. Damage that occurs in the molecule, cell, and tissues affects the physiological functions and leads to many diseases [1], as cardiovascular diseases, diabetes and neurodegenerative disorder [2].

Aging is influenced by genetic factors, environmental factors, and reactive oxidative species (ROS) [3,4].

Cells are the basic building block of a body. Tissues are groups of cells that have a similar structure, and different kinds of tissues together form an organ. As changes occur in cells and tissues, organs also experience the changes of ageing.

The liver is one of the largest organs in the body and plays a central role in metabolic processes. hepatocyte (liver cell), hepatic stellate cell, Kupffer cell are basic structures involved in liver. Liver carries, blood, nutrients, medication, and toxic substances. These substances are processed, deposited, modified, detoxified, and return to the blood or released into bowels to be eliminated, thus we can observe the changes in the basic structure of the liver with aging. Even with an incredible ability to heal itself, the liver has vulnerabilities with alcohol, infections, toxins, and a general genetic disorder [5]. Kidney act as a filter to remove waste products, maintain healthy balances of water, salt, and minerals [6]. kidney shows changes in nephrons, in number of glomeruli, and cortical volume. As kidney stops functioning toxin begins to build up in the body, eventually, this leads to liver failure [7]. The continuous function of detoxification and filtration leads to changes in structures of hepatocytes (liver cells), hepatic sinusoidal endothelial cells, Kupffer cells of liver and nephron, glomeruli, cortical volume of the kidney. These changes would consequently have direct impact on the functional capacity of the organ liver and kidney. Thus ageing becomes a major risk factor for a variety of liver and kidney diseases [8,9].

Acharya Charaka indicates to use the vayasthapana mahakashaya for vayasthapana purpose. Acharya Chakrapani stated that vayasthapana means vayastarunsthapayalitii vayasthapana [10], which means establishing the young stage of life. This suggests that vayasthapana mahakashaya may have a property to keep the body organs healthy for a long time. And healthy organs perform their functions properly and maintain their structural integrity and strength for a long time. The use of vayasthapana mahakashaya may prove beneficial in regards to aging changes that occur in body organs.

Vayasthapana mahakashaya mentioned in the text is a combination of ten drugs. It’s very difficult to evaluate the exact effect of each drug on the structure of the organs.

Charakacharya has mentioned using the drugs in combination or individual as per requirement [11].

The individual effect of guduchi (Tinospora cardifolia) against carbon tetrachloride-induced hepatic damage, cadmium induce oxidative stress and hepatotoxicity [12] and gentamycin-induced renal toxicity has been studied [13,14]. Similarly, the individual effect of punarnava (Boerhavia diffusa) on gentamicin-induced nephrotoxicity and thioacetamide intoxicated rats

Keywords: Aging; guduchi; punarnava; vayasthapana; liver; kidney.
has been studied [15,16]. Animal experiment carried out to investigate organ toxicity profile of tenofovir and tenofovir nano particle on liver and kidney [17] However, combined effect of guduchi and punarnava drugs have not been studied by previous researchers in intoxicated rats, also the solitary effect of guduchi and punarnava on normal age-related structural and functional changes occurs in the liver and kidney in the animal experiment not studied. Thus an attempt will be made to study the solitary effect of guduchi and punarnava and combination effect of these two on structural and functional age-related changes that occur in liver and kidney of Wistar rats. The antioxidant properties of combined guduchi and punarnava kwath will be studied.

2. MATERIALS AND METHODS

2.1 Plant Materials

The raw material will be collected from Manas Ayurveda, Nagpur. Identification and authentication of raw material will be done by the subject expert of Dravyaguna or Botanist.

2.2 Preparation of Test Drug

The raw materials of guduchi kwath, punarnava kwath, guduchi and punarnava kwath will be separately shade dried and disintegrated into fine pieces and powdered by hammer mill pulverizer of mesh size 60 and boiled with water in the ratio of 1:16 and reduced to 1/8 and filtered through fine cloth [18].

2.3 Animal Experiment

Male Wistar rats of age 18 months [19], weighing between 150-280 gm will be selected for the experiment. A total of 32 rats will be divided into four different groups of 8 animals in each group as follows:

- Group 1- normal control group received only distilled water
- Group 2 - treated with guduchi kwath (GK) with a dose of 8.1ml/kg.
- Group 3 - treated with punarnava kwath (PK) with a dose of 8.1ml/kg.
- Group 4 - treated with guduchi and punarnava kwath (GPK) with a dose of 8.1ml/kg.

2.4 Dose Selection and Fixation

A dose of 90 ml of kashaya will be fixed to adult rats as per the Bhavprakash Nighantu [20]. Dose fixation will be calculated by extrapolating the human dose to animal’s dose based on ratio of body surface area with reference to the table of Paget and Barnes [21].

Conversion formula: = Human Dose × 0.018 (conversion factor for Rat)

Test drug guduchi kwath, punarnava kwath, guduchi punarnava kwath dose.

= Human Dose × 0.018 (conversion factor for Rat)
= 90 × 0.018 = 1.62ml/200g body weight of Rat
= 8.1ml/kg

2.5 Route of Administration

Orally with help of 2 ml syringe.

2.6 Antioxidant Assay DPPH [22]

1,1-diphenyl-2-picrylhydrazine (DPPH) radical scavenging assays are one of the most extensively used authentic activity of the extract (kwatha). It is mentioned in terms of radical scavenging ability or hydrogen donating capacity using the stable radical DPPH. The authentication activity will be measured at 515 nm after thirty minutes of incubation. DPPH solution 300 um will be prepared in methanol and 95 ul of DPPH will be added to each well, prepared kwatha of drug, 5 ul will be added to the respective well. Ascorbic acid will be used as a positive control.

The scavenging activity percentage is calculated with the help of following formula

Percentage of scavenging = \left[ \frac{AC – AS}{AC} \right] * 100

Where
AC – is absorbance of control
AS – is absorbance of sample (guduchi+punarnava)

A huge reduction in the absorbance of the reaction mixture indicates the significant free radical scavenging activity of the drug compound.

2.7 Animal Experimental Procedure

Thirty-two rats will be divided into four different groups of 8 animals each.

- Group 1, normal control (NC) group received only distilled water
Group 2 treated with *guduchi kwath* (TGG) with a dose of 8.1ml/kg.
Group 3 treated with *punarnava kwath* (TGP) with a dose of 8.1ml/kg.
Group 4 treated with *guduchi* and *punarnava kwath* (TGPP) with a dose of 8.1ml/kg.

After than at the end of 60 days two animals from each group will be sacrificed by administering a light dose of ether anesthesia, blood will be collected by jugular vein for assessment of LFT, KFT, and SOD level. The liver and kidney will be separated and preserved in formalin and for histological studies. Similarly, at the end of 120 days two animals, from each group, will be sacrificed and liver and kidney will be separated and preserved in formalin for histological studies. The last two animals, from each group, after 180 days will be sacrificed by the administration of the light dose of ether anesthesia, blood will be collected by jugular vein for assessment of LFT, KFT and SOD level. The liver, and kidney will be separated and preserved in formalin for the histological studies. (Fig. 1).

### Table 1. Drug intervention plan

| GrNo | Group name                  | Age       | Group code | Sample size | Intervention/dose | Route of drug administration |
|------|----------------------------|-----------|------------|-------------|-------------------|-------------------------------|
| 1    | Normal control group -     | 18 months | NC         | 8           | Distilled water   | Oral                          |
| 2    | Trial group *guduchi*      | 18 months | TGG        | 8           | *Guduchi kwath*   | Oral                          |
| 3    | Trial group *punarnava*    | 18 months | TGP        | 8           | *Punarnava kwath* | Oral                          |
| 4    | Trial group *guduchi* and *punarnava* | 18 months | TGPP       | 8           | *Guduchi and Punarnava kwath* | Oral                      |

### 2.8 Outcome Measures

![Assessment criteria for structural and functional changes of organ](image)

- **SOD Activity assay score**
- **Structural changes**
  1. Liver - Histopathological report
  2. Kidney - Histopathological report
- **Functional Changes**
  1. LFT
  2. KFT

**Fig. 1. Outcome measures**

### 2.9 Methods of Data Collection

Data will be collected by laboratory reports and histology reports.

### 2.10 Statistical Analysis Methods

All data management will be done in an excel sheet. All the values will be expressed as mean, mean± standard deviation. Statistical significance will be analyzed using the student ‘t’ test. repeated measure ANOVA followed by post hoc test will use to assess the statistical significance between the different groups. Results will be considered on a 95% confidence limit. All the statistical analyses will be performed using statistical software SPSS.
2.11 Expected Results

Guduchi and punarnava may provide strength to organ liver and kidney and helpful in delaying degenerative changes of Organ.

3. DISCUSSION

Drugs of Vayasthapan mahakashaya guduchi and punarnava may be the better source of natural antioxidants and it may be helpful to prevent and delay damage to cells and contribute to the development of a noble treatment strategy that can delay the progression of degeneration. It may help in delaying aging process in individuals also. A number of studies on different liver conditions [23-26] and kidney diseases [27-30] were reviewed. Khan et al. reported a study on Evaluation of In Vitro Anti-Cancer Activity of Kukkutanakhi Guggula on Liver, Prostrate, Ovary and Renal Cancer [31]. Similar studies on Rat and Mice models were reported by Khatib et al. [32,33].

4. CONCLUSION

Ageing becomes a major risk factor for liver and kidney diseases. Conclusion will be made on the basis of would be result, the effect of guduchi and punarnava on structural and functional changes on organ liver and kidney may helpful in delaying age and better functioning of the organ.

CONSENT

It is not applicable.

ETHICAL APPROVAL

Protocol is approved by institutional animal ethics committee.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Rodríguez-Rodero S, Fernández-Morera JL, Menéndez-Torre E, Calvanese V, Fernández AF, Fraga MF. Aging Genetics and Aging. Aging Dis. 2011; 2(3):186–95.
2. McHugh D, Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol. 2018;217(1):65–77.
3. McHugh D, Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol. 2018;217(1):65–77.
4. Cui K1, Luo X, Xu K, Ven Murthy MR. Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical authentications. 2004;28(5):771-99.
5. Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. How does the liver work? [Internet]. InformedHealth.org [Internet]. Institute for Quality and Efficiency in Health Care (IQWiG); 2016. [Cited 2020 Sep 17]. Available:https://www.ncbi.nlm.nih.gov/booksn NK279393/
6. Bankir L, Bouby N, Trinh-Trang-Tan M-M. 2 The role of the kidney in the maintenance of water balance. Baillièrre’s Clinical Endocrinology and Metabolism. 1989;3(2):249–311.
7. A Slack, A Yeoman and J. Wendon, Renal dysfuction in chronic liver disease. BMC. 2010;214.
8. Kim H, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31(3):184–91.
9. Weinstein JR, Anderson S. The aging kidney: Physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–7.
10. Agnivesha, Charaka, Dridhabala, Charak Samhita, Chakrapani commentary, Sutra Sthana, Shadhvirchaniya Shritiya Adhyay, 4/8, edited by Sharma PV, Reprint ed. Chaukhamba Orientalia, Varanasi. 2011;32.
11. Agnivesha, Charaka, Dridhabala, Charak Samhita, Chakrapani commentary, Sutra Sthana, Shadhvirchanastrashatrayi Adhyay, 4/28-29, edited by Sharma PV, Reprint ed. Chaukhamba Orientalia, Varanasi. 2011;36.
12. Baskaran R, Priya LB, Sathish Kumar V, Padma VV. Tinospora cordifolia extract prevents cadmium-induced oxidative stress and hepatotoxicity in experimental rats. Journal of Ayurveda and Integrative Medicine. 2018;9(4):252–7.
13. Kavitha BT, Shruthi SD, Rai SP, Ramachandra YL. Phytochemical analysis and hepatoprotective properties of Tinospora cordifolia against carbon tetrachloride-induced hepatic damage in rats. Journal of Basic and Clinical Pharmacy. 2011;2(3):139.
14. Sharma M, Pundir J, Vishwakarma P, Goel RK, Saini M, Saxena KK. Evaluation of
nephroprotective activity of Tinospora cordifolia against gentamicin induced nephrotoxicity in albino rats: an experimental study. International Journal of Basic & Clinical Pharmacology. 2019;8(6):1179–84.

15. Sawardekar SB, Patel TC. Evaluation of the effect of Boerhavia diffusa on gentamicin-induced nephrotoxicity in rats. Journal of Ayurveda and Integrative Medicine. 2015;6(2):95.

16. Rawat AK, Mehrotra S, Tripathi SC, Shome U. Hepatoprotective activity of Boerhaavia diffusa L. roots—a popular Indian ethnomedicine. J Ethnopharmacol. 1997;56(1):61–6.

17. Peter AI, Naidu EC, Akang E, Ogedengbe OO, Offor U, Rambharose S, et al. Investigating Organ Toxicity Profile of Tenofovir and Tenofovir Nanoparticle on the Liver and Kidney: Experimental Animal Study. Toxicol Res. 2018;34(3):221–9.

18. Tripathi B, Sharangdhar Samhita of the Liver and Kidney: Experimental Study. Toxicol Res. 2018;34(3):221–9.

19. Andreollo NA, Santos EFD, Araujo MR, Lopes LR. Rat's age verses human's age: What is the relationship?. ABCDbArq Bras Cir Dig. 2012;25:49-51.

20. The Ayurvedic Pharmacopoeia of India of Government of India, Ministry of Health and Family Welfare, Department of AYUSH, Part – I, First edition, Delhi: The Controller of Publications. I:261.

21. Authentications (NAO) of Plants Acting as Scavengers of Free Radicals – Science Direct [Internet]. [Cited 2020 Jan 14].

22. Kedare SB, Singh RP. Genesis and development of DPPH method of antioxidant assay. J Food Sci Technol. 2011;48(4):412–22.

23. Husain A, Chiwhane A, Kinmake V. Non-invasive assessment of liver fibrosis in alcoholic liver disease. Clinical and Experimental Hepatology. 2020;6(2):125–30. Available:https://doi.org/10.5114/ceh.2020.95739

24. Jain Jyoti, Ramji Singh, Shashank Banait, Nitin Verma, Satish Waghmare. Magnitude of Peripheral Neuropathy in Cirrhosis of Liver Patients from Central Rural India. Annals of Indian Academy of Neurology. 2014;17(4):409–15.

25. Arya SH, Deshpande S, Belwal P, Sharma P, Sadana Chandrakant F, Rahman M Gupta, et al. Association between cardiac dysfunction, arrhythmias and chronic liver diseases: A Narrative Review. Trends in Anaesthesia and Critical Care 2020;32:4–12. Available:https://doi.org/10.1016/j.tacc.2020.03.003

26. Arya Sanjeev, Hemant Deshpande, Shantanu Belwal, Preeti Sharma, Punish Sadana, Chandrakant, et al. Association between cardiac dysfunction, arrhythmias and chronic liver diseases: A narrative review. Trends in Anaesthesia and Critical Care 32, 2020;4:12. Available:https://doi.org/10.1016/j.tacc.2020.03.003

27. Jain J, Banait S, Tiewsoh I, Choudhari M. Kikuchi’s Disease (Histiocytic Necrotizing Lymphadenitis): A rare presentation with acute kidney injury, peripheral neuropathy, and aseptic meningitis with cutaneous involvement. Indian Journal of Pathology and Microbiology. 2018;61(1):113–15. Available:https://doi.org/10.4103/IJPM.IJP M_256_17

28. Balwani MR, Bawankule C, Pasari A, Tolani P, Vakil S, Yadav R. Minimal change disease and kimura’s disease responding to tacrolimus therapy. Saudi Journal of Kidney Diseases and Transplantation. 2018;30(1):254–57. Available:https://doi.org/10.4103/1319-2442.252921

29. Balwani M, Bawankule C, Ramteke V, Pasari A. Hepatitis C Virus, Directly acting antivirals and guillain-barré syndrome. Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2018;29(5):1237–39. Available:https://doi.org/10.4103/1319-2442.243969

30. Balwani MR, Bawankule C, Khetan P, Ramteke V, Tolani P, et al. An uncommon cause of rapidly progressive renal failure in a lupus patient: pauci-immune crescentic glomerulonephritis. Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2018;29(4):989–92.
Available:https://doi.org/10.4103/1319-2442.239632
31. Khan Mujahid B, Ninad Sathe, Bharat Rathi. Evaluation of In vitro anti-cancer activity of kukkutanakhi guggula on liver, prostrate, ovary and renal cancer. International Journal of Ayurvedic Medicine. 2020;11(3):491–96.
32. Khatib Mahalaqua Nazli, Anuraj Shankar, Richard Kirubakaran, Kingsley Agho, Padam Simkhada, Shilpa Gaidhane, et al. Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: A Systematic review. Annals of Tropical Medicine and Public Health. 2014;7(1):30–42. Available:https://doi.org/10.4103/1755-6783.145008
33. Khatib, Mahalaqua Nazli, Dilip Gode, Padam Simkhada, Kingsley Agho, Shilpa Gaidhane, et al. Somatotropic and cardio-protective effects of ghrelin in experimental models of heart failure: A Systematic review and meta-analysis. PLOS ONE. 2015;10(5). Available:https://doi.org/10.1371/journal.pone.0126697